Novavax INC 8-K filings

Novavax provided a strategic update at the Jefferies London Healthcare Conference, highlighting its partnership with Sanofi, pipeline advancements, and cost reduction efforts.

The FDA has lifted the clinical hold on Novavax's COVID-19-Influenza Combination and stand-alone influenza vaccine candidates, allowing the company to proceed with its Phase 3 trial.

Novavax announced its third quarter 2024 financial results, highlighted by $85 million in revenue and progress in its R&D strategy, including the removal of a clinical hold on its combination vaccine candidate.

Novavax has reached a settlement with the UK Health Security Agency, agreeing to refund $123.8 million related to a terminated vaccine supply agreement.

Novavax's COVID-19-Influenza Combination and standalone influenza vaccine trials have been placed on clinical hold by the FDA due to a serious adverse event reported in a Phase 2 trial participant.

Novavax clarifies that while it anticipates the U.S. COVID-19 vaccination market to be similar to last year, it has not updated or reaffirmed its full-year 2024 financial guidance.

Novavax announced strong second-quarter 2024 results, highlighted by a $415 million revenue and a significant partnership with Sanofi.

Novavax stockholders approved amendments to the company's stock incentive and employee stock purchase plans, increasing the number of shares available for issuance.

Novavax provided a strategic update, highlighting its partnership with Sanofi, progress on its COVID-19 vaccine, and plans for future growth and cost reduction.

Filip Dubovsky, President of Research and Development at Novavax, will retire effective June 30, 2024, and will transition to a consulting role.

Novavax has entered into a major collaboration and licensing agreement with Sanofi, granting Sanofi rights to commercialize Novavax's COVID-19 vaccines and adjuvant technology, while securing a $500 million upfront payment and up to $1.6 billion in potential milestone payments.

Novavax has entered into a co-exclusive licensing agreement with Sanofi, representing a potential multi-billion dollar revenue opportunity, and reported its first quarter 2024 financial results.

Novavax has amended its bylaws to lower the quorum requirement for stockholder meetings from a majority to one-third of outstanding shares, effective April 22, 2024.

Novavax has reached a settlement with Fujifilm, paying $42 million to resolve disputes over a prior manufacturing agreement and avoiding further arbitration.

Novavax announced its Q4 and full year 2023 financial results, highlighting a revenue of $291 million for the quarter and $1 billion for the year, alongside a significant restructuring and progress on a combination vaccine.

Novavax has reached a settlement with Gavi, terminating their prior agreement and agreeing to a $475 million payment, including an initial payment and deferred annual payments.

Novavax is reducing its global workforce by approximately 12% as part of a cost-cutting initiative.